Aptose Biosciences Inc. Announces Closing of $8 Million Public Offering
November 25, 2024 16:15 ET
|
Aptose Biosciences, Inc.
Aptose Biosciences Inc. Announces Closing of $8 Million Public Offering
Aptose Biosciences Inc. Announces Pricing of $8 Million Public Offering
November 22, 2024 08:00 ET
|
Aptose Biosciences, Inc.
Aptose Biosciences Inc. Announces Pricing of $8 Million Public Offering
Aptose Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-based Triplet Therapy
November 20, 2024 07:30 ET
|
Aptose Biosciences, Inc.
Aptose Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-based Triplet Therapy
Aptose Reports Results for the Third Quarter 2024
November 08, 2024 16:01 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly...
Aptose Announces Results from Special Meeting of Shareholders
September 05, 2024 16:15 ET
|
Aptose Biosciences, Inc.
Aptose Announces Results from Special Meeting of Shareholders
Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib
August 30, 2024 16:30 ET
|
Aptose Biosciences, Inc.
Aptose Receives $10 Million Through a Facility Agreement with Hanmi;
Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib
Aptose Announces Adjournment of its Special Meeting of Shareholders
August 15, 2024 16:30 ET
|
Aptose Biosciences, Inc.
Aptose Announces Adjournment of its Special Meeting of Shareholders
Aptose Reports Results for the Second Quarter 2024
August 08, 2024 17:06 ET
|
Aptose Biosciences, Inc.
Aptose Reports Results for the Second Quarter 2024
Aptose Announces Receipt of Deficiency Notice from Nasdaq
July 19, 2024 17:00 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, July 19, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly...
Aptose Announces Results from Annual and Special Meeting of Shareholders
June 18, 2024 17:30 ET
|
Aptose Biosciences, Inc.
Aptose Announces Results from Annual and Special Meeting of Shareholders